Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Administration of Deucravacitinib with Placebo (2 arms). Primary endpoints: Psoriasis Area and Severity Index 75 at 16 weeks and Static Physician's Global Assessment 0 or 1 at 16 weeks. Started Dec 2025; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06979453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979453.